Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biowa who wrote (11)	6/26/1997 8:46:00 PM
From: Pseudo Biologist	of 3044

Just an excuse to keep the board from going down to the archives again ... Reviewing some press releases I see that obesity and artherosclorosis have moved to the stage of compound screening; this is being done by the respective corporate partners. This may mean that they have chosen one or very few gene targets. This sounds to me as if these two areas to some extent are past the point of target validation, wouldn't you say? Also, some interesting trading action over the last week or so, with Perseptive dumping half the shares they got from the ChemGenics deal. This is part of the December press release regarding artherosclorosis: Wednesday December 4 8:08 AM EDT Millennium Announces Genetics-Based Atherosclerosis Target is Ready for Drug Candidate Screening Millennium to Receive Milestone Payment CAMBRIDGE, Mass., Dec. 4 /PRNewswire/ -- A new development in the search for drugs to prevent or treat atherosclerosis occurred today as Millennium Pharmaceuticals Inc announced that a gene-based assay developed jointly at Eli Lilly and Company and Millennium is ready to enter screening at Lilly to identify atherosclerosis drug candidates. This represents the most advanced development to date in the Millennium/Lilly alliance in the field of atherosclerosis, which began in October of 1995, and is the second gene-based drug discovery effort at Millennium to reach the drug candidate screening stage. The assay will move into a high-throughput drug screening program at Lilly within the next several weeks, at which point Millennium will receive a milestone payment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next